SRR27320676
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 80.75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.640
- DNA_REPAIR+0.420
- MYC_TARGETS_V1+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
- FATTY_ACID_METABOLISM+0.340
- INTERFERON_ALPHA_RESPONSE+0.300
- ADIPOGENESIS+0.280
- INTERFERON_GAMMA_RESPONSE+0.280
- CHOLESTEROL_HOMEOSTASIS+0.270
- ALLOGRAFT_REJECTION+0.240
Top 10 suppressed
- MITOTIC_SPINDLE-0.520
- HEDGEHOG_SIGNALING-0.500
- WNT_BETA_CATENIN_SIGNALING-0.440
- ANGIOGENESIS-0.360
- APICAL_JUNCTION-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- G2M_CHECKPOINT-0.260
- UV_RESPONSE_DN-0.260
- APICAL_SURFACE-0.250
- KRAS_SIGNALING_DN-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 57901dc3-9b2f-4271-8dd9-8fc0121d6971 | — | — | 0.880 |
| 2 | TCGA-49-4488-01A-01R-1755-07 | — | cohortA1 | 0.875 |
| 3 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.846 |
| 4 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.843 |
| 5 | TCGA-37-4133-01A-01R-1100-07 | — | cohortSQ1 | 0.841 |
| 6 | SRR9879275 | — | cohortA1 | 0.836 |
| 7 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.835 |
| 8 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.830 |
| 9 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.829 |
| 10 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.640 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |